InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$13.13|
|52 Week High||US$11.65|
|52 Week Low||US$23.26|
|1 Month Change||-13.51%|
|3 Month Change||-26.03%|
|1 Year Change||0.15%|
|3 Year Change||291.94%|
|5 Year Change||380.95%|
|Change since IPO||144.96%|
Recent News & Updates
|INFU||US Healthcare||US Market|
Return vs Industry: INFU underperformed the US Healthcare industry which returned 37.7% over the past year.
Return vs Market: INFU underperformed the US Market which returned 36.2% over the past year.
Stable Share Price: INFU is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: INFU's weekly volatility (10%) has been stable over the past year.
About the Company
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates through two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment (DME) Services. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.
InfuSystem Holdings Fundamentals Summary
|INFU fundamental statistics|
Is INFU overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|INFU income statement (TTM)|
|Cost of Revenue||US$39.39m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.74|
|Net Profit Margin||15.25%|
How did INFU perform over the long term?See historical performance and comparison
Is InfuSystem Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: INFU ($13.13) is trading below our estimate of fair value ($39.72)
Significantly Below Fair Value: INFU is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: INFU is good value based on its PE Ratio (17.9x) compared to the US Healthcare industry average (22x).
PE vs Market: INFU is poor value based on its PE Ratio (17.9x) compared to the US market (17.7x).
Price to Earnings Growth Ratio
PEG Ratio: INFU is good value based on its PEG Ratio (0.8x)
Price to Book Ratio
PB vs Industry: INFU is overvalued based on its PB Ratio (6x) compared to the US Healthcare industry average (3.2x).
How is InfuSystem Holdings forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INFU's forecast earnings growth (22.2% per year) is above the savings rate (2%).
Earnings vs Market: INFU's earnings (22.2% per year) are forecast to grow faster than the US market (14.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: INFU's revenue (12.7% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: INFU's revenue (12.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: INFU's Return on Equity is forecast to be high in 3 years time (22.5%)
How has InfuSystem Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INFU has high quality earnings.
Growing Profit Margin: INFU's current net profit margins (15.2%) are higher than last year (6.3%).
Past Earnings Growth Analysis
Earnings Trend: INFU's earnings have grown significantly by 50.6% per year over the past 5 years.
Accelerating Growth: INFU's earnings growth over the past year (166.5%) exceeds its 5-year average (50.6% per year).
Earnings vs Industry: INFU earnings growth over the past year (166.5%) exceeded the Healthcare industry 32.2%.
Return on Equity
High ROE: INFU's Return on Equity (33.8%) is considered high.
How is InfuSystem Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: INFU's short term assets ($21.7M) exceed its short term liabilities ($15.8M).
Long Term Liabilities: INFU's short term assets ($21.7M) do not cover its long term liabilities ($35.4M).
Debt to Equity History and Analysis
Debt Level: INFU's debt to equity ratio (72.6%) is considered high.
Reducing Debt: INFU's debt to equity ratio has increased from 65.5% to 72.6% over the past 5 years.
Debt Coverage: INFU's debt is well covered by operating cash flow (76.5%).
Interest Coverage: INFU's interest payments on its debt are well covered by EBIT (5.2x coverage).
What is InfuSystem Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INFU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INFU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INFU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INFU's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of INFU's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rich DiIorio (46 yo)
Mr. Richard A. DiIorio, also known as Rich, joined InfuSystem Holdings Inc. in 2004 and serves as its Chief Executive Officer and Director since November 15, 2017. He served as President at InfuSystem Hold...
CEO Compensation Analysis
Compensation vs Market: Rich's total compensation ($USD3.20M) is above average for companies of similar size in the US market ($USD1.09M).
Compensation vs Earnings: Rich's compensation has increased by more than 20% in the past year.
Experienced Management: INFU's management team is not considered experienced ( 2 years average tenure), which suggests a new team.
Experienced Board: INFU's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
InfuSystem Holdings Inc.'s employee growth, exchange listings and data sources
- Name: InfuSystem Holdings Inc.
- Ticker: INFU
- Exchange: NYSEAM
- Founded: 2005
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$264.922m
- Shares outstanding: 20.57m
- Website: https://www.infusystem.com
Number of Employees
- InfuSystem Holdings Inc.
- 3851 West Hamlin Road
- Rochester Hills
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/23 23:03|
|End of Day Share Price||2021/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.